At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
AZD9668 +1 moredrug
Likely dose
AZD9668 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.
In Brief
A Phase 2 clinical trial evaluating AZD9668 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 52 participants across 9 sites in 5 countries.
Detailed Summary
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Denmark, Netherlands, Romania, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJan 2010
Primary CompletionNov 2010
TodayJul 2026
First PostedJan 22, 2010
Enrollment StartJan 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.4 years ago
Interventions
AZD9668drug
2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Placebodrug
2 x matched placebo to oral tablet twice daily (bid) for 12 weeks